SFM
APLS

Sphera Funds Management’s Apellis Pharmaceuticals APLS Stock Holding History

Sphera Funds Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60,000
Closed -$3.1M – 83
2022
Q4 		$3.1M Buy
+60,000
New +$3.18M 0.67% 38

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sphera Funds Management's APLS Position: Q1 2026 in Review

Sphera Funds Management reduced its Apellis Pharmaceuticals (APLS) stake by 14% in Q1 2026, selling an estimated $777K and leaving 214,914 shares worth $8.65M. The position accounts for 1.37% of the portfolio, ranked #16.

Sphera Funds Management first reported a position in APLS in Q2 2018 and has held it in 10 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Sphera Funds Management held 214,914 shares of Apellis Pharmaceuticals worth $8.65M as of Q1 2026.
  • Sphera Funds Management sold 36,047 Apellis Pharmaceuticals shares in Q1 2026, an estimated $777K.
  • Apellis Pharmaceuticals made up 1.37% of Sphera Funds Management's portfolio in Q1 2026, its #16 holding.
  • Sphera Funds Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 10 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.